Clarus Therapeutics Holdings

Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical…

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be listed in FDA’s Orange Book, bringing…

NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic…

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce results from the trial in the first half…

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic…

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated…

NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men…

Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases…